Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

NCT01639508 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Cabozantinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]